AbbVie’s Skyrizi (risankizumab-rzaa) Receives FDA’s Approval for Moderate to Severe Plaque Psoriasis

 AbbVie’s Skyrizi (risankizumab-rzaa) Receives FDA’s Approval for Moderate to Severe Plaque Psoriasis

AbbVie’s Skyrizi (risankizumab-rzaa) Receives FDA’s Approval for Moderate to Severe Plaque Psoriasis

Shots:

  • The approval is based on four P-III ultIMMa-1, ultIMMa-2, IMMhance and IMMvent studies results assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in patients with moderate to severe plaque psoriasis
  • The P-III ultIMMa-1 & ultIMMa-2 result: @16 wks. PASI 90 (75% vs 5% & 2%); PASI 100 (36% & 51% vs 0% & 2%); @52wks. PASI 90 (82% & 81% vs 56% & 60%); @16 wks. integrated results showed maintenance of PASI 90 and PASI 100 for 1yr. (88% & 80%) respectively
  • Skyrizi (risankizumab-rzaa) is an IL-23 inhibitor that works by binding to p19 subunit, administered four doses/yr. after two initial doses and has received MHLW approval for plaque psoriasis, Health Canada approval and EMA’s CHMP positive opinion for moderate-to-severe plaque psoriasis with its expected regulatory decision in EU and availability in the US in H1’19 & May’19 respectively

Click here to read full press release/ article | Ref: Abbvie | Image: Pharmaceutical Technology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post